Healthcare Providers and Services
Company Overview of Hackensack University Medical Center
Hackensack University Medical Center operates as a nonprofit teaching and research hospital that provides inpatient and outpatient services in New Jersey. It offers medical services in the areas of cancer, cardiac, emergency, endocrinology, home health, internal medicine, pediatric healthcare for children, and obstetrics and gynecology; and surgical services covering ambulatory, bariatric, breast, cardiothoracic, colorectal, general, oncologic, pediatric, vascular, and plastic and reconstructive surgeries, as well as wound management, organ transplantation, trauma/surgical critical care, neurology and neurosurgery, orthopedic care, and urology. The company also offers specialized services in...
30 Prospect Avenue
Hackensack, NJ 07601
Founded in 1888
Key Executives for Hackensack University Medical Center
Chief Executive Officer, President, Member of Board of Governors, Member of Advisory Board, Ex-officio Member of Finance Committee, Ex-officio Member of Audit & Compliance Committee, Ex-officio Member of Board Development Committee and Ex-officio Member of Governance Committee
Chief Financial Officer, Executive Vice President and Member of Audit & Compliance Committee
Chief Strategy and Operations Officer, Executive Vice President and Member of Audit & Compliance Committee
Chief Executive Officer of Pascack Valley
Executive Vice President of Patient Care Division and Chief Nursing Officer
Compensation as of Fiscal Year 2014.
Hackensack University Medical Center Key Developments
John Theurer Cancer Center Joins Study Exploring Novel Delivery of Cancer-Selective Gene Therapy to Treat Brain Cancer
Mar 18 15
Physicians at the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center announced their involvement in a promising multicenter Phase 1 study assessing the safety and tolerability of Toca 511 in patients with glioblastoma, the most common and lethal form of brain cancer. Toca 511 is a retroviral replicating vector that has been engineered to deliver a therapeutic gene selectively to brain tumor cells while sparing healthy brain tissue. In this study, sponsored by Tocagen Inc., Toca 511 is injected directly into the brain tumor through a stereotactic biopsy needle. Once injected, Toca 511 infects tumor cells, sparing healthy functioning brain cells. During the following weeks, patients are then given cycles of an oral medication, 5-flucytosine (5-FC), an antifungal drug that readily enters the brain. The infected tumor cells now carry genetic instructions for an enzyme that converts 5-FC into 5-fluorouracil (5-FU), a highly-potent chemotherapy that destroys cancer cells, which may lead to activation of the immune system against the tumor. Currently ongoing, the study will enroll up to 50 patients with glioblastoma and other aggressive high-grade gliomas (Grade 3 or 4) who have already undergone surgery, radiation therapy and chemotherapy. Among the estimated 13,000 new cases of high-grade glioma each year in the United States, glioblastoma is the most common and aggressive, with only 5% of patients surviving to five years after diagnosis.
Seton Hall University and Hackensack University Medical Center Plans to Build Private Medical School
Jan 15 15
Seton Hall University and the parent company of Hackensack University Medical Center are planning to build a private medical school that could open in 2017.
Hackensack University Medical Center Presents at Milken Institute Global Conference 2014, Apr-29-2014 08:00 AM
Apr 26 14
Hackensack University Medical Center Presents at Milken Institute Global Conference 2014, Apr-29-2014 08:00 AM. Venue: Lon Angeles, California, United States. Speakers: Manny Alvarez, Chairman, Department of Obstetrics and Gynecology.
Similar Private Companies By Industry
Recent Private Companies Transactions